Article

Avastin: a new hope for corneal transplant patients?

Topical bevacizumab (Avastin) has shown excellent preliminary results and good topical tolerance when used in the prevention of corneal transplant failure.

Topical bevacizumab (Avastin) has shown excellent preliminary results and good topical tolerance when used in the prevention of corneal transplant failure, according to Jose Güell and Merce Morral, from Instituto de Microcirugìa Ocular (IMO) de Barcelona, Spain, speaking at "The endothelium: new surgical and medical concepts" symposium.

Irreversible immune rejection is one of the leading causes of corneal graft failure. Preoperative measures to prevent graft rejection aim to minimize the antigenic difference between the host and the donor tissues, while a careful and precise surgical technique including centration of the graft, optimal suturing and sound graft-host application may also contribute to the prevention of graft rejection.

In order to reduce deep stromal vascularization of the host cornea, Dr Güell is subconjunctivally injecting 0.1 mL of Avastin, beginning with its use under topical administration, and his results with the off-label agent have been promising so far.

Dr Güell advised that topical and systemic steroids remain the standard for the prevention of corneal graft rejection, while oral azathioprine, cyclosporine (CsA) and other immunosuppressive drugs such as FK506 and mycophenolate mofetil are also clinically used for prevention. Sustained release drug delivery systems (DDS) of CsA and FK506 have been developed to avoid systemic side effects while maintaining therapeutic levels in the anterior segment of the eye.

Dr Güell concluded that although there have been developments in the improvement of pharmacological strategies to prevent corneal transplant, further research is needed to find new agents with better efficacy and safety.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.